SHAMLOO (STANDFORD UNIVERSITY) - MCSP-EXPLORATORY CHEMISTRY (EC)

SHAMLOO（斯坦福大学）- MCSP-探索化学（EC）

• 批准号: 10720930
• 负责人: KEITH BARNES
• 金额: $ 65.69万
• 依托单位: ALBANY MOLECULAR RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-05-06 至 2023-11-05
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10720930
• 关键词: Academia; Basic Science; Biotechnology; Chemistry; Clinic; Clinical Trials; Data; Development; Drug Formulations; Drug Kinetics; Funding; Goals; Grant; Human; Institutes; Institution; Intellectual Property; Lead; Licensing; Nervous system structure; Neurosciences Research; Pharmaceutical Chemistry; Pharmaceutical Preparations; Phase; Phase I Clinical Trials; Property Rights; Research; Research Personnel; Research Support; Risk; Testing; Toxicology; Translating; United States National Institutes of Health; Universities; clinical candidate; drug development; drug discovery; experience; nervous system disorder; novel; novel therapeutics; programs; research clinical testing; small molecule; success

SHAMLOO (STANDFORD UNIVERSITY) - MCSP-EXPLORATORY CHEMISTRY (EC) The NIH Blueprint Neurotherapeutics Network (BPN) is part of NIH Blueprint for Neuroscience Research, a collaborative framework that includes the NIH Office of the Director together with eleven NIH Institutes and Centers, that support research on the nervous system. The BPN was launched to enable neuroscientists in academia and biotechnology companies to develop new drugs for nervous system disorders. The BPN provides non-dilutive funding for small molecule drug discovery and development, from hit-to-lead chemistry through phase I clinical testing. Through the BPN program, investigators together with the NIH build a team and leverage drug discovery and development experts who can help them advance their basic research into human testing. This is accomplished through a combination of grant funding and access to a full range of NIH-funded drug discovery development CROs (medicinal chemistry, pharmacokinetics/ADME, toxicology, drug manufacturing, drug formulation and phase I clinical trials) and, most importantly, access to NIH funded consultants with extensive pharma experience spanning all drug development stages to help guide the team. A fundamental hallmark of the program is that the research institution retains the intellectual property rights. With a strong track record of success, the BPN program provides an excellent opportunity to translate basic and applied findings into novel clinical candidates and advance them to the clinic. The goal is to generate the required data to de-risk further funding for subsequent clinical trials, partnership, or out-licensing.

SHAMLOO（斯坦福大学）-MCSP-探索化学（EC） NIH Blueprint Neurotherapeutics Network（BPN）是NIH Blueprint for Neuroscience Research的一部分，这是一个合作框架，包括NIH主任办公室以及11个NIH研究所和中心，支持神经系统研究。 BPN的推出是为了使学术界和生物技术公司的神经科学家能够开发治疗神经系统疾病的新药。BPN为小分子药物的发现和开发提供非稀释性资金，从命中到铅化学到I期临床试验。通过BPN计划，研究人员与NIH一起建立了一个团队，并利用药物发现和开发专家来帮助他们将基础研究推进到人体测试中。 这是通过赠款资金和获得全方位的NIH资助的药物发现开发CRO（药物化学，药代动力学/ADME，毒理学，药物制造，药物配方和I期临床试验）的组合来实现的，最重要的是，获得NIH资助的顾问，他们具有跨越所有药物开发阶段的丰富制药经验，以帮助指导团队。该计划的一个基本特点是研究机构保留知识产权。凭借强大的成功记录，BPN计划提供了一个极好的机会，将基本和应用发现转化为新的临床候选人，并将其推向临床。 其目标是生成所需的数据，以降低后续临床试验、合作伙伴关系或外部许可的进一步资金风险。